A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
for Atopic Dermatitis
33 locations incl. Birmingham
Sponsor: Apollo Therapeutics Ltd
Sex: All·Age: 18 - 65
Code: NCT07599813·Phase 2·Recruiting·Listed May 2026